Strafford will be offering a webinar entitled "Functional Claiming for Software Patents: Leveraging Recent Court Treatment -- Surviving 112(f) and Disclosing Functional Basis for Software to Meet Heightened Standard of Review" on June 5, 2018 from 1:00 to 2:30 pm (EDT). Cory C. Bell and Doris Johnson Hines of Finnegan Henderson Farabow Garrett & Dunner will guide IP counsel on functional claiming in software patents and USPTO prosecution, examine recent court treatment, and explain how to navigate the issue of functionality given the uncertainties in the prosecution and litigation contexts.
Sigma Labs has several additional patents pending related to its PrintRite3D technology. This recently granted patent is for the first application of 18 submitted over the past five years in the general domain of in process quality assurance.
Protecting and Navigating Intellectual Property for Artificial Intelligence Based Technologies
[...]
...AI data processing systems, has seen an increase of 500%. While increasing numbers of AI technology patents are issuing, as with other kinds of computer-implemented inventions, AI-based inventions are generally vulnerable to being considered ineligible subject matter.
As technology advances, artificial intelligence (AI)-generated inventions – i.e., inventions created autonomously or semi-autonomously by computer systems – are deemed to becoming more common. The human ingenuity in such inventions is less visible, while at the same time the inventing activity becomes easier, as most of the mental effort is passed on to the AI. However, this scenario makes it harder to assess whether the invention possesses an “inventive step” – a condition for patentability that requires the invention to be non-obvious to a skilled person. Indeed, a given AI-generated invention might be non-obvious to a skilled person; but it will probably be obvious to a person that has access to a similar AI. The main aim of this research is to assess whether patent laws are fit for purpose with regard to the patentability of AI-generated inventions, in particular in what concerns the inventive step requirement. With that objective, the research carries out a comparative analysis of the inventive step (or non-obviousness) requirement in Japan, the European Union and the United States. The research will conclude with recommendations towards an international harmonization of the interpretation of, and practices related to, the inventive step requirement in the field of AI-generated inventions.
Open Source Software is also in the cross-hairs of numerous cloud patent lawsuits. It’s no surprise that patent trolls would target open source, such as Sound View’s lawsuit against Fidelity directed at multiple OSS components, including jQuery, OpenStack Object Storage (Swift), Apache HBase, and Apache Storm. Sound View also filed earlier lawsuits against open source software usage of major cloud service providers such as Hulu, Facebook, Twitter and LinkedIn. What did come as a surprise were the patent infringement allegations that Citrix leveled against Avi Networks’ cloud application delivery platform for OpenStack, mentioned above in the context of cloud competitor lawsuits.
[...]
Overall, patent litigation filings in 2018 are on par, if somewhat below, the number of filings in 2017. However, in a fascinating development, the number of Non-NPE patent lawsuits exceeds the number of NPE lawsuits for the first time in years, according to Unified Patents Q1 2018: Patent Dispute Report.
[...]
On the other hand, the change in patent venue law and subsequent decline of the Eastern District of Texas as the hotbed of patent litigation ushered in by TC Heartland will require NPEs to continue evolving their litigation tactics. On balance, however, these actions collectively may increase the strength and certainty of U.S. patents after a decade of what many see as an assault on patent value by the Supreme Court in particular. If that trend holds, and patents become more powerful (and valuable), cloud patent lawsuits will certainly be on the rise in the coming years.
The Federal Circuit has held that patent claims directed to “performing certain statistical analyses of investment information” are patent-ineligible under the Alice/Mayo abstract idea test and 35 U.S.C. €§ 101, thus affirming a District Court’s judgment on the pleadings. SAP America, Inc. v. InvestPic, LLC, No. 2017-2081 (Fed Cir. May 15, 2018) (precedential) (opinion by Judge Taranto), joined by Judges Lourie and O’Malley). In the second paragraph of its opinion, the court emphasized that brilliant innovation would not alone save patent-eligibility, nor could novelty and non-obviousness under 35 U.S.C. €§€§ 102 and 103.
Following a jury trial, the court granted plaintiff's motion for judgment as a matter of law because the asserted claims of plaintiff’s labrador retriever genotyping patent encompassed unpatentable subject matter and found that the claims were directed toward a natural phenomenon.
The court granted plaintiff's motion for summary judgment because the asserted claims of its pain treatment patents did not encompass unpatentable subject matter and found that the claims were not directed toward a law of nature.
In a divided opinion, the Federal Circuit held that all of the claims challenged in an IPR were obvious, upholding the PTAB’s obviousness determination with respect to most of the claims but reversing its nonobviousness determination with respect to a few. Praxair Distribution raises of a number of distinct, yet interrelated, issues concerning the cryptic, yet essential, printed matter doctrine: the opinion addresses the doctrine’s extension to mental steps, its implications for the relationship between sections 101 and 102/103, and the breadth of its functional-relation exception.
U.S. Patent 8,846,112 covers methods of distributing nitric oxide gas cylinders for pharmaceutical applications. Inhaling nitric oxide dilates blood vessels in the lungs and improves blood oxygenation, and it is approved for treating neonates with hypoxic respiratory failure. The prior art taught that inhaled nitric oxide may lead to pulmonary edema, a serious adverse event, in neonates with left ventricular dysfunction. The claims of the ‘112 patent address methods that build on this prior art. Roughly, the claims can be sorted into three groups: the informing claims, the informing-and-evaluating claims, and the informing-and-discontinuing-treatment claims. This commentary addresses each of these three groups of claims in turn.